Peptilogics

Peptilogics is a clinical-stage biotechnology company dedicated to the design and development of novel peptide therapies. Through its computational platform, Peptilogics not only discovers previously unexplored new chemical design spaces but also ensures that each potential therapeutic agent is biologically viable and manufacturable at scale, fundamentally transforming drug discovery. Peptilogics' leading clinical-stage peptide therapeutic, PLG0206, is a novel broad-spectrum anti-infective agent. Due to its initial focus on treating prosthetic joint infections (an unmet medical need), it has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation.